For the quarter ending 2026-03-31, ALNY made $1,167,175K in revenue. $201,194K in net income. Net profit margin of 17.24%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 1,167,175 | 1,097,033 | 1,249,026 | 773,689 |
| Cost of goods sold | 207,520 | 267,723 | 197,231 | 142,029 |
| Cost of collaborations and royalties | 3,602 | 0 | 2,923 | 924 |
| Research and development | 364,866 | 372,218 | 358,814 | 323,621 |
| Selling, general and administrative | 322,551 | 325,374 | 322,076 | 323,314 |
| Total operating costs and expenses | 898,539 | 965,315 | 881,044 | 789,888 |
| Income from operations | 268,636 | 131,718 | 367,982 | -16,199 |
| Interest expense | 69,286 | 129,337 | 44,398 | 40,246 |
| Interest income | 26,598 | 26,630 | 28,681 | 27,486 |
| Gain related to convertible debt | - | 3,327 | 39,146 | - |
| Other (expense) income, net | -4,295 | 135,453 | -74,150 | -6,399 |
| Total other expense, net | -46,983 | 29,419 | -129,013 | -19,159 |
| Income (loss) before income taxes | 221,653 | 161,137 | 238,969 | -35,358 |
| Provision for income taxes | 15,662 | -25,282 | -12,115 | 30,919 |
| Net income (loss) | 205,991 | 186,419 | 251,084 | -66,277 |
| Unrealized (gaines) losss on marketable securities | -3,652 | -2 | 1,131 | -343 |
| Foreign currency translation gaines | -1,234 | 858* | 6,993 | 7,855 |
| Defined benefit pension plans, net of tax | -89 | -822* | -53 | -53 |
| Net other comprehensive income (gain) | -4,797 | 1,678 | 8,177 | 7,565 |
| Comprehensive income (loss) | 201,194 | 188,097 | 259,261 | -58,712 |
| Basic EPS | 1.55 | 1.422 | 1.91 | -0.51 |
| Diluted EPS | 1.51 | 1.333 | 1.84 | -0.51 |
| Basic Average Shares | 132,893,000 | 132,265,000 | 131,447,000 | 130,628,000 |
| Diluted Average Shares | 138,226,000 | 141,084,000 | 137,348,000 | 130,628,000 |
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)